Veronica Murianni, Alessio Signori, Sebastiano Buti, Sara Elena Rebuzzi, Davide Bimbatti, Ugo De Giorgi, Silvia Chiellino, Luca Galli, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Michele Milella, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Veronica Mollica, Mariella Sorarù, Marianna Tudini, Veronica Prati, Andrea Malgeri, Francesco Atzori, Marilena Di Napoli, Orazio Caffo, Massimiliano Spada, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Helga Lipari, Giandomenico Roviello, Fabio Catalano, Alessandra Damassi, Malvina Cremante, Pasquale Rescigno, Giuseppe Fornarini, Giuseppe Luigi Banna
BACKGROUND: Immunotherapies exhibit peculiar cancer response patterns in contrast to chemotherapy and targeted therapy. Some patients experience disease response after initial progression or durable responses after treatment interruption. In clinical practice, immune checkpoint inhibitors may be continued after radiological progression if clinical benefit is observed. As a result, estimating progression-free survival (PFS) based on the first disease progression may not accurately reflect the actual benefit of immunotherapy...
2024: Frontiers in Oncology